Skip to Main Content
For healthcare professionals

Beamion™ PANTUMOR‑1: Phase II study of zongertinib in HER2‑altered solid tumors (NCT06581432)

 

Beamion™ PANTUMOR-1: A Phase II, multi-center, multi-cohort, open-label trial to evaluate the efficacy and safety of oral zongertinib for the treatment of selected HER2-mutated or HER2-overexpressed/amplified solid tumors (NCT06581432)1,2

zongertinib: NCT06581432 (Beamion™ PANTUMOR-1, 1479-0009
zongertinib: NCT06581432 (Beamion™ PANTUMOR-1, 1479-0009

*Exception: tumor agnostic cohorts; †Biliary tract cancer includes cholangiocarcinoma, gallbladder, and ampullary cancers.
DoR, duration of response; HER2, human epidermal growth factor 2; NSCLC, non-small cell lung cancer; OR, objective response; PFS, progression-free survival; QOL, quality of life; TEAE, treatment-emergent adverse event.

References

  1. ClinicalTrials.gov. NCT06581432. https://clinicaltrials.gov/study/NCT06581432 (Accessed: February 2026).

  2. Schram AM, et al. ASCO 2025. Poster TPS3187.